The calculation and use of economic burden data

British Journal of Ophthalmology

Volumn 90, Issue 3, 2006, Pages 255-257

  Frick, Kevin D ^a   Kymes, S M ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHRITIS; CANCER; CATARACT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMENTIA; DEVELOPED COUNTRY; DIABETIC RETINOPATHY; DISEASE COURSE; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; EDITORIAL; EYE CARE; GLAUCOMA; HEALTH CARE POLICY; HUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; VISUAL IMPAIRMENT;

COST OF ILLNESS; DEVELOPED COUNTRIES; HUMANS; QUALITY-ADJUSTED LIFE YEARS; VISION DISORDERS;

EID: 33644647280     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.084848     Document Type: Editorial

References (6)

1. Frick KD, Foster A, Bah M, et al. Analysis of costs and benefits of the Gambian Eye Care Program. Arch Ophthalmol 2005;123:239-43.
2. Kenkel D. On valuing morbidity, cost-effectiveness analysis, and being rude. J Health Econ 1997;16:749-57.
3. Alberini A. What is a life worth? Robustness of VSL values from contingent valuation surveys. Risk Anal 2005;25:783-800.
4. Pauly MV. Valuing health care benefits in money terms. In: Sloan FA, eds. Valuing health care: costs, benefits, and effectiveness of pharmaceutical and other medical technologies. New York: Cambridge University Press, 1995.
5. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-42.
6. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-4.